MESO

Mesoblast Ltd

Add to Watchlist

Advanced Chart

16.360

-0.62(-3.651%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

16.600

Open

16.580

VWAP

16.46

Vol

213.38K

Mkt Cap

20.94B

Low

16.260

Amount

3.51M

EV/EBITDA(TTM)

Total Shares

114.12M

2.21B

EV/OCF(TTM)

P/S(TTM)

330.33

Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.

1 Analyst Rating

83.37% Upside

Wall Street analysts forecast MESO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MESO is 30.00 USD with a low forecast of 30.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

83.37% Upside

Current: 16.360

Low

30.00

Averages

30.00

High

30.00

83.37% Upside

Current: 16.360

Low

30.00

Averages

30.00

High

30.00

Jefferies

David Stanton

Buy

Hold

downgrade

2025-07-18

Reason

Jefferies

David Stanton

Price Target

2025-07-18

downgrade

Buy

Hold

Reason

Jefferies analyst David Stanton downgraded Mesoblast to Hold from Buy with a price target of A$2.60, up from A$2.50, following the fiscal Q4 report. The firm estimates 68 paid infusions were given during the quarter of Ryoncil in the U.S. with six patents likely having completed treatment. Jefferies updated fiscal 2025 estimates and awaits the company's annual results in August.

Piper Sandler

Edward Tenthoff

Buy

Reiterates

$15 → $24

2025-02-07

Reason

Piper Sandler

Edward Tenthoff

Price Target

$15 → $24

2025-02-07

Reiterates

Buy

Reason

Jefferies

David Stanton

Strong Buy

Hold

Downgrades

n/a

2024-12-23

Reason

Jefferies

David Stanton

Price Target

n/a

2024-12-23

Downgrades

Strong Buy

Hold

Reason

Jefferies downgraded Mesoblast to Hold from Buy with a price target of A$2.30, up from A$1.10. The firm updated the company's for the FDA'ss recent approval of Ryoncil in pediatric steroids-refractory acute graft-versus-host disease patients. While the market size is only 375 pediatric patients per year in the U.S., expansion of this indication is possible in adults if the upcoming adult trial is positive, the analyst tells investors in a research note. Jefferies continues to assume full U.S. reimbursement approval at the start of fiscal 2026. However, after Mesoblast's recent share price appreciation, the firm downgraded the shares on valuation.

Piper Sandler

Edward Tenthoff

Buy

Maintains

$11 → $15

2024-12-19

Reason

Piper Sandler

Edward Tenthoff

Price Target

$11 → $15

2024-12-19

Maintains

Buy

Reason

Maxim Group

Jason McCarthy

Hold

Strong Buy

Upgrades

$12

2024-09-24

Reason

Maxim Group

Jason McCarthy

Price Target

$12

2024-09-24

Upgrades

Hold

Strong Buy

Reason

Maxim upgraded Mesoblast to Buy from Hold with a $12 price target.

Cantor Fitzgerald

Louise Chen

Buy

Reiterates

n/a

2024-08-29

Reason

Cantor Fitzgerald

Louise Chen

Price Target

n/a

2024-08-29

Reiterates

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Mesoblast Ltd (MESO.O) is -29.13, compared to its 5-year average forward P/E of -10.84. For a more detailed relative valuation and DCF analysis to assess Mesoblast Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-10.84

Current PE

-29.13

Overvalued PE

-2.28

Undervalued PE

-19.41

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-20.93

Current EV/EBITDA

-60.46

Overvalued EV/EBITDA

6.15

Undervalued EV/EBITDA

-48.01

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

30.73

Current PS

42.86

Overvalued PS

48.80

Undervalued PS

12.66